Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
A 1.66 9.93% 0.15
CDTX closed up 11.03 percent on Friday, February 3, 2023, on 2.1 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 9.93%
New 52 Week High Strength 9.93%
Parabolic Rise Strength 9.93%
Wide Bands Range Expansion 9.93%
Gapped Up Strength 9.93%
Up 3 Days in a Row Strength 9.93%
Up 4 Days in a Row Strength 9.93%
Upper Bollinger Band Touch Strength 9.93%
Calm After Storm Range Contraction 22.06%
Wide Bands Range Expansion 22.06%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 1 hour ago
Up 10% about 1 hour ago
Up 1 ATR about 1 hour ago
Down 3% about 6 hours ago
Down 2 % about 6 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cidara Therapeutics, Inc. Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Infectious Diseases Immunotherapy Vagina Anti Infectives Immunotherapy Technology

Is CDTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.63
52 Week Low 0.4
Average Volume 1,408,915
200-Day Moving Average 0.68
50-Day Moving Average 0.84
20-Day Moving Average 1.16
10-Day Moving Average 1.22
Average True Range 0.16
RSI 69.51
ADX 32.72
+DI 43.89
-DI 15.13
Chandelier Exit (Long, 3 ATRs) 1.15
Chandelier Exit (Short, 3 ATRs) 1.21
Upper Bollinger Bands 1.55
Lower Bollinger Band 0.77
Percent B (%b) 0.95
BandWidth 66.86
MACD Line 0.15
MACD Signal Line 0.13
MACD Histogram 0.0178
Fundamentals Value
Market Cap 66.35 Million
Num Shares 43.9 Million
EPS -2.14
Price-to-Earnings (P/E) Ratio -0.70
Price-to-Sales 9.13
Price-to-Book 3.42
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.87
Resistance 3 (R3) 1.87 1.75 1.81
Resistance 2 (R2) 1.75 1.66 1.75 1.79
Resistance 1 (R1) 1.63 1.60 1.69 1.63 1.77
Pivot Point 1.51 1.51 1.54 1.51 1.51
Support 1 (S1) 1.39 1.42 1.45 1.39 1.25
Support 2 (S2) 1.27 1.36 1.27 1.23
Support 3 (S3) 1.15 1.27 1.21
Support 4 (S4) 1.15